March 18, 2021
• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]
January 19, 2021
DS Biopharma (DS) has successfully submitted two abstracts to the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference. A link to the abstract “Steroid-sparing […]
November 19, 2019
The following article appeared in Dermatology Times on 19th November 2019: https://www.dermatologytimes.com/atopic-dermatitis/pipeline-full-agents-various-phases-development As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data […]
March 6, 2019
Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]
November 19, 2018
Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]
October 3, 2018
DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis Dublin, Ireland, October 3rd 2018 […]